ULBP2 and chronic myelogenous leukemia, BCR-ABL1 positive: The adriamycin-resistant chronic myeloid leukemia (CML) cell line K562 is killed more efficiently by NK cells upon treatment with a STAT3 inhibitor and shows an upregulation of MICA and ULBP2 (59).